EGFR and Parkinson disease: Integrating clinical data, such as PD duration and medication history, with molecular findings could clarify whether dysregulation varies across disease stages or treatments, ultimately strengthening evidence for NMDAR and EGFR signaling in impaired wound healing in PD.